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Abstract
Objective: Galunisertib (LY2157299 monohydrate), an inhibitor 
of the transforming growth factor β (TGFβ) pathway, is currently 
under investigation in several clinical trials involving multiple 
tumor types. The primary objective of this study was to assess 
relative bioavailability of two new galunisertib formulations 
developed using the roller compaction (RC) dry-milled (RCD) 
and RC slurry-milled (RCS) processes, compared with the 
existing formulation developed using the high-sheer wet 
granulation (HSWG) process. The secondary objective was 
to report the safety profile after a single dose of the three 
formulations.
Methods: Patients with advanced or metastatic cancer 
were enrolled into this single-center, 3-period, 6-sequence 
crossover study. Patients were assigned sequentially to 1 of 6 
sequences in blocks of 6 to ensure that all 6 sequences have 
the same number of completers. A patient entering a sequence 
received a different galunisertib formulation as a single 150 
mg dose orally during each of the 3 periods. Each period was 
separated from the next by a washout interval of at least 48 
hours. Pharmacokinetic (PK) parameters, including area under 
curve (AUC) and Cmax, were computed using standard non-
compartmentalized methods of analysis. For comparison of 
exposures between formulations, log-transformed AUC and 
Cmax values were analyzed using a linear mixed-effects model. 
Safety assessments included adverse event monitoring, physical 
examinations, and laboratory tests.
Results: Of the 14 patients who entered and completed the 
study, 13 patients were included in the final statistical analysis. 
AUC(0-tlast), AUC(0-48 h), and AUC(0-∞) for the RC formulations 
and the HSWG formulation were similar. Cmax was reduced 
by approximately 22% and tmax was longer by at least 1.00 h 
for the RCD and RCS formulations compared with the HSWG 
formulation. The RC formulations demonstrated a safety profile 
after a single dose similar to the HSWG formulation. 
Conclusions: In this relative bioavailability study comparing 
galunisertib formulations after a single dose, RCD and RCS 
formulations had similar exposure and safety profile compared 
with the HSWG formulation. 
Keywords: LY2157299, transforming growth factor beta, area 
under curve, biological availability, half-life, pharmacokinetics, 
neoplasms, adverse drug event.
Abbreviations: AE, adverse events; API, active pharmaceutical 
ingredient; AUC, area under curve; Cmax, maximum plasma 
drug concentration; CI, confidence interval; CTCAE v3.0, 
common terminology criteria for adverse events version 3.0; CV, 
coefficient of variation; ECOG, Eastern Cooperative Oncology 
Group; FHD, first-in-human dose; HSWG, high-sheer wet 
granulation; ICD, informed consent declaration; LC/MS, liquid 
chromatography/mass spectrometry; LSM, least squares mean; 
PD, pharmacodynamics; PK, pharmacokinetic; PS, performance 
status; RBA, relative bioavailability; RC, roller compaction;  
RCD, roller compaction dry-milled; RCS, roller compaction 
slurry-milled; SAE, serious adverse events; TEAEs, treatment-
emergent adverse events; TGFβ, transforming growth  
factor β
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Introduction
Transforming growth factor-β ligands (TGFβ1, TGFβ2, and 
TGFβ3) play an important role in the tumorigenesis and 
progression of several tumors [1,2]. These ligands signal via  
the TGFβRI and TGFβRII receptors to activate a signaling 
cascade involving SMAD proteins [3]. TGFβ signaling is 
activated in several malignancies including gliomas [4], 
hepatocellular carcinoma [5] and pancreatic cancer [6]. 
Galunisertib (LY2157299 monohydrate), an oral small- 
molecule inhibitor of TGFβRI and TGFβRII, is currently under 
investigation in several clinical trials involving multiple tumor 
types [7]. Galunisertib is well absorbed with peak plasma 
concentrations attaining around 0.5–2 hours following 
administration and with mean terminal half-life of 8 hours 
[8]. The effect of gut pH on galunisertib absorption has been 
studied previously, where we reported that galunisertib  
in solution or tablet products maintained supersaturation 
during transit in the gastrointestinal tract [9]. To reduce  
the impact of change in pH after a meal, galunisertib has  
thus far been administered to patients only in fasted state.  
Based on a pharmacokinetic (PK)/ pharmacodynamics (PD) 
model, a therapeutic window for galunisertib administration  
(160–300 mg/day) has been defined for phase II/III studies 
[10]. At 150 mg BID on an intermittent dosing schedule  
(14 days on/14 days off on a 28-day cycle), galunisertib has  
a favorable safety profile with very few grade 3/4 adverse 
events (AEs) [8,10].
The galunisertib tablet formulation used for early clinical 
studies was initially developed and manufactured using a  
high-sheer wet granulation (HSWG) process. The HSWG 
process was developed initially to minimize the possible 
impact of physical property variability of the incoming active 
pharmaceutical ingredient (API) that may be observed early 
in development. A roller compaction (RC) dry granulation 
process was subsequently developed to maintain sufficient 
tablet strength to allow film coating. RC tablets were 
manufactured using API that was dry milled (RCD) to achieve 
particle size reduction (x90 of 50 µm). A separate batch 
of RC tablets was manufactured using API that was slurry 
milled (RCS, x90 of 80 µm). These RC tablets were compared 
in a Relative Bioavailability (RBA) study to a single batch of 
HSWG tablets manufactured with only dry milled API (x90 
of 50 µm). Therefore, the RBA study compared API of two 
different particles sizes (x90 of 50 µm and x90 of 80 µm) and 
two different oral solid manufacturing platforms (HSWG and 
RC). It was expected that the in vivo PK profile of the 3 tablet 
presentations would be similar based on in vitro experiments 
[9]. However, a clinical evaluation was necessary for further 
clinical development of these galunisertib formulations. The 
objective of this study was to assess the PK profile and safety 
after a single dose of these two RC formulations relative to the 
HSWG formulation in patients with advanced or metastatic 
cancer. 
Methods
Study design and study drug 
administration
This relative bioavailability study is an addendum to the 
first-in-human dose (FHD) study of galunisertib in patients 
with advanced or metastatic cancer, results from which have 
been reported previously [8,11]. The study was an open-label, 
3-period, 6-sequence crossover study conducted at a single 
investigational site in patients with advanced or metastatic 
cancer who had exhausted all available therapeutic options. 
Patients were grouped into sets of 6 with each patient in a 
set being assigned sequentially to 1 of 6 possible treatment 
sequences (Supplementary Table S1). Patients received 
galunisertib formulations as RCS 150 mg (3 × 50 mg), RCD  
150 mg or HWSG 150 mg, orally on the first day of each of the  
3 treatment periods (Figure 1). If a patient discontinued from the 
study treatment in any period, another patient was enrolled into 
that sequence starting from period 1. A washout interval of at 
least 48 hours and up to a maximum of 5 days separated each 
period. During each period, approximately 4 mL of venous blood 
and the resultant plasma samples were used for measurement 
of galunisertib concentrations using a liquid chromatography/
mass spectrometry (LC/MS) method. The samples were collected 
at intervals up to 48 hours following each dose. Patients were 
monitored for safety throughout the study. Patients who 
completed the study were allowed to take part in the main 
protocol of the FHD study, in which they received galunisertib 
150 mg BID in the HSWG formulation as monotherapy. 
The study was conducted in accordance with the principles as 
defined in the most recent version of the Declaration of Helsinki 
for human experimentation. The study protocol was approved 
by the Institutional Review Board of the investigational site. 
Informed consent declaration (ICD) was obtained from each 
patient after they had been made aware of the potential risks 
and benefits, as well as the investigational nature of the study. 
All patients were given the option to roll-over to the main 
protocol of the study and be treated with galunisertib until 
disease progression.
Bioanalytical methods
Plasma samples were analyzed for galunisertib using  
2 validated liquid chromatography methods coupled with 
tandem mass spectrometry [8]. For the high-range method, the 
lower and upper limit of quantification was 5.000 ng/mL and 
1000.000 ng/mL, respectively. For samples above the upper 
limit of quantification of the high-range method, reanalysis 
was done after dilution to yield results within the calibrated 
range. For the low-range method, the lower and upper limits 
of quantifications were 0.050 ng/mL and 10.000 ng/mL, 
respectively. The intra-assay accuracy and precision during 
validation have been described previously [8]. 
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Pharmacokinetic analyses
Primary PK parameters were maximum plasma drug 
concentration (Cmax) and area under the curve (AUC). Other 
parameters included half-life (t1/2), volume of distribution (Vz/F), 
and clearance (CL/F). All these parameters were computed 
using standard non-compartmental methods of analysis. 
Statistical analyses of pharmacokinetic 
parameters
A sample size of 12 patients was planned for this study, which 
is the minimum number recommended in the USFDA guidance 
for any cross-over bioavailability study [12]. Log-transformed 
values of AUC and Cmax were analyzed using a linear mixed-
effects model with sequence, period and treatment groups 
being treated as fixed effects, and subject treated as a random 
effect. Least squares mean (LSM) for each treatment group 
and 90% confidence interval (CI) for the mean of the pairwise 
differences were estimated using this model. After back 
transformation from the log scale, estimates of geometric 
LSM and 90% CI for the ratio of means were calculated. Times 
to maximum plasma drug concentration (tmax) values were 
analyzed using the non-parametric Wilcoxon signed-rank test 
to obtain the medians of pairwise differences and their 90% CI.
Safety analyses
Safety assessments included monitoring for AEs and serious 
adverse events (SAEs), physical examinations, vital sign 
measurements, laboratory tests, and review of concomitant 
medications. AEs were assessed according to the Common 
Terminology Criteria for Adverse Events version 3.0 (CTCAE 
v3.0) and treatment-emergent adverse events (TEAEs) were 
included in the safety analyses. All patients receiving at least 1 
dose of galunisertib were included in the safety analyses.
Results
Patient disposition
All 14 patients who entered the study received at least 1 dose 
of the study drug and completed 3 periods.
Patient demographics
The mean age of patients was 59.8 years; all patients 
were White (100%) and majority were female (64%). Of 
the total number of patients, 86% of the patients had a 
baseline Eastern Cooperative Oncology Group (ECOG) 
performance status (PS) of 0 or 1, 79% had recurrent 
disease at study entry, and 64% had a pathological 
diagnosis of glioma, namely, glioblastoma and 
astrocytoma (Table 1). 
Pharmacokinetic analysis
Plasma concentrations of galunisertib from all patients were 
included in the PK evaluations. The final statistical analysis 
of AUC, Cmax, and tmax excluded a patient (R77) with colon 
adenocarcinoma as the primary tumor, who was recovering 
from an underlying infection with associated inflammation. 
This patient showed substantially higher exposures that  
varied considerably as the inflammation resolved (assessed 
using CRP biomarker, not shown) across the 3 study periods 
(Figure 3). The patient had AUC0-∞ values of 12,500, 10,900  
and 20,100 g*h/L for HSWG, RCD and RCS formulations, 
respectively (Figure 3). In comparison, the geometric mean 
of AUC0-∞ values in the study were 4,740, 4,490 and 4,790 
µg*h/L for HSWG, RCD and RCS formulations, respectively 
(Table 2). The statistical analysis including the data from this 
patient (N=14) is presented in Supplementary Table S2 and 
Supplementary Table S3.
Figure 1. Study design.
aTo allow for site scheduling flexibility, an extra 1-day interval between dosing periods was allowed (ie, if the third day of a 
period fell on a Saturday, the next period may have begun on Monday).  
bMinimum of 2 days, maximum of 5 days.
Abbreviations: h = hour; HSWG = high-sheer wet granulation; PK = pharmacokinetic; RCD = roller compaction dry-milled (test 
formulation 2); RCS = roller compaction slurry-milled (test formulation 1).
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of causality. The most common TEAE was grade 3 lymphopenia 
which was experienced by 2 patients. All other TEAEs were of 
grade 1 severity (Table 5). None of the TEAEs were determined 
to be related to galunisertib by the investigator. There were no 
study discontinuations due to TEAEs. There were also no SAEs 
or deaths during this study. 
Values for CL/F, Vz/F, and t1/2 parameters of galunisertib 
were similar for all three formulations (Table 2). Exposures 
as defined by AUC [0-tlast], AUC [0-48 h], and AUC [0-∞] were 
comparable between the RCD and RCS formulations, and the 
HSWG formulation (Table 3). Cmax of galunisertib was lower 
for the RCD and RCS formulations by approximately 22% 
compared with the HSWG formulation (Table 3). Additionally, 
the median tmax of galunisertib was longer for the RCD and RCS 
formulations (2.00 h) compared with the HSWG formulation 
(1.00 h) (Table 4). The mean and individual plasma concentrations 
of galunisertib over a period of 48 hours are shown in Figures 2 
and 3, respectively.
Safety and tolerability
All 14 patients were included in the safety analysis in this single 
dose study. Five of the 14 patients reported 7 TEAEs regardless 
Table 1. Patient baseline characteristics.
Variable Galunisertib
(any formulation)
N=14
Age, years
 Mean 59.8
 Median (range) 56.5 (34–76)
Sex, n (%)
 Female 9 (64.0)
 Male 5 (36.0)
Origin, n (%)
 Caucasian 14 (100)
ECOG performance status,  
n (%)
 0 4 (28.6)
 1 8 (57.1)
 2 2 (14.3)
Initial pathological diagnosis, 
n (%)
Astrocytoma 2 (14.3)
Choroidal melanoma 1 (7.1)
Colon adenocarcinoma 1 (7.1)
Glioblastoma 7 (50.0)
Hepatocellular carcinoma 2 (14.2)
Pancreatic adenocarcinoma 1 (7.1)
Stage of disease at study entry, 
n (%)
Metastatic 3 (21.4)
Recurrent 11 (78.6)
Abbreviations: ECOG = Eastern Cooperative Oncology 
Group; N = number of patients who received drug.
Table 2. Non-compartmental pharmacokinetic 
parameters of the three formulations of 
galunisertib.
Parametersa Galunisertib (150 mg)
HSWG
(N=14)
RCD
(N=14)
RCS
(N=14)
tmax
b 
(h)
1.00
(0.50–3.08)
2.00
(0.50–3.17)
2.00
(0.50–3.00)
Cmax 
(µg/L)
954 
(89.7)
734 
(68.0)
769 
(67.8)
AUC(0-12) 
(µg·h/L)
3,430 
(64.6)
3,170 
(56.1)
2,970 
(63.0)
AUC(0-24) 
(µg·h/L)
4,070 
(61.5)
3,840 
(53.7)
3,660 
(64.3)
AUC(0-tlast) 
(µg·h/L)
4,520 
(58.5)
4,360 
(52.0)
4,350 
(63.9)
AUC(0-48) 
(µg·h/L)
4,520 
(58.6)
4,360 
(52.0)
4,340 
(63.8)
AUC(0-∞) 
(µg·h/L)
4,740 
(55.6)
4,490c 
(53.3)
4,790d 
(70.9)
CL/F  
(L/hr)
31.7 
(55.6)
33.4c 
(53.3)
31.3d 
(70.9)
Vz/F 
(L)
505 
(88.0)
473c 
(76.0)
511d 
(81.9)
t1/2 
(h)
11.1 
(47.0)
9.81c 
(41.1)
11.3d 
(42.4)
aAll pharmacokinetic parameters except tmax 
evaluated after a single dose on Day 1 of each period 
are geometric mean (% CV) (unless stated otherwise). btmax 
is median (range); cN=12; dN=11. AUC(0-∞), CL/F, Vz/F,  
and t1/2 not reported for patients where extrapolated 
AUCtlast-inf>20%.
Abbreviations: AUC = area under the plasma 
concentration versus time curve; AUC(0-∞) = AUC 
from zero to infinity; AUC(0-tlast) = AUC from time 
zero to time t where t is the last time point with a 
measurable concentration; AUC(0-x) = AUC from time 
zero to time x where x is the last time point with a 
measurable concentration; CL/F = clearance; Cmax = 
maximum plasma drug concentration; CV = coefficient 
of variation; HSWG = high-sheer wet granulation; N = 
number of subjects used in pharmacokinetic analysis; 
RCD = roller compaction dry-milled; RCS = roller 
compaction slurry-milled; t1/2 = half-life associated 
with the terminal rate constant in non-compartmental 
analysis; tmax = time of maximum plasma drug 
concentration; Vz/F = volume of distribution.
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disadvantage of a roller-compacted process is the loss of 
compactability, resulting in tablets with lower than acceptable 
tensile strength. However, this risk was mitigated through 
the use of extragranular powders in both the RCD and RCS 
process, producing tablets of adequate hardness, low friability, 
and fast disintegration/dissolution, meeting all critical quality 
attributes. The PK profile for galunisertib tablets (150 mg BID) 
manufactured using the HSWG process has been established 
Discussion
The HSWG process has been used to manufacture galunisertib 
tablet formulations for use in early clinical trials. The RCD 
and RCS processes for galunisertib tablets were developed 
to minimize the risk of physical instability often associated 
with wet granulation. The RC processes are also easier to scale 
up which is important for commercialization. A potential 
Table 3. Analysis of AUC and Cmax of galunisertib.
Parameter Formulation,
150 mg
N Geometric 
LSM
(90% CI)
Ratio of 
geometric 
LSM
RCD/
RCS:HSWG
(90% CI)
AUC(0-tlast) 
(µg∙h/L)
HSWG 13 3,795
(3,267, 4,410)
RCD 13 3,704
(3,188, 4,304)
0.98 (0.83, 
1.15)
RCS 13 3,497
(3,009, 4,065)
0.92 (0.78, 
1.08)
AUC(0-48)  
(µg∙h/L)
HSWG 13 3,797
(3,268, 4,413)
RCD 13 3,702
(3,186, 4,302)
0.97 (0.83, 
1.14)
RCS 13 3,489
(3,001, 4,056)
0.92 (0.78, 
1.08)
AUC(0-∞)  
(µg∙h/L)
HSWG 13 4,026
(3,449, 4,699)
RCD 11 3,921
(3,328, 4,621)
0.97 (0.84, 
1.13)
RCS 10 3,842
(3,246, 4,547)
0.95 (0.81, 
1.12)
HSWG 13 859
(618, 1,194)
Cmax 
(µg/L)
RCD 13 666
(479, 925)
0.77 (0.57, 
1.06)
RCS 13 667
(479, 927)
0.78 (0.57, 
1.06)
One patient (R77) who showed substantially higher 
exposures as explained in results was excluded from 
analysis. For AUC(0-∞), 2 and 3 patients for RCD and RCS, 
respectively had extrapolated AUC(tlast-inf) values >20% 
and could not be included in the analysis. 
Abbreviations: AUC = area under the plasma concentration 
versus time curve; AUC(0-∞) = AUC from zero to infinity;  
AUC(0-48) = AUC from zero to 48 hours postdose;  
AUC(0-tlast) = AUC from time zero to time t where t is  
the last time point with a measurable concentration;  
CI = confidence interval; Cmax = maximum plasma drug 
concentration; HSWG = high-sheer wet granulation;  
LSM = least squares means; N = number of patients;  
PK = pharmacokinetic; RCD = roller compaction dry-
milled; RCS = roller compaction slurry-milled.
Table 4. Analysis of tmax of galunisertib.
Parameter Formulation,
150 mg
N Median
(min, max)
Median 
difference 
RCD/RCS – 
HSWG 
(90% CI)
HSWG 13 1.00
(0.50, 3.00)
tmax 
(h)
RCD 13 2.00
(0.50, 3.17)
0.59
(0.00, 1.25)
RCS 13 2.00
(0.50, 3.00)
0.00
(0.00, 0.75)
One patient (R77) who showed substantially higher 
exposures as explained in results was excluded from 
analysis. 
Abbreviations: CI = confidence interval; HSWG = high-
sheer wet granulation; max = maximum; min = minimum; 
N = number of patients; RCD = roller compaction dry-
milled; RCS = roller compaction slurry-milled; tmax = time 
of maximum plasma drug concentration. 
Figure 2. Mean plasma concentration-time profiles 
of formulations of galunisertib.
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150 mg, single dose, do not change. This may help decide  
if the new formulations can be taken forward for further  
clinical development. 
In this relative bioavailability study, exposures as defined by 
AUC over different time periods (AUC[0-tlast], AUC[0-48], and 
AUC[0-∞]) of RCD and RCS formulations were comparable with 
the HSWG formulation (Table 3). The ratios of geometric LSM 
of AUC[0-∞] values of RCD and RCS formulations relative to the 
HSWG formulation (i.e. RCD/RCS:HSWG) were 0.97 (90% CI:0.84, 
1.13) and 0.95 (90% CI:0.81, 1.12) for RCD and RCS, respectively 
(Table 3). However, Cmax was at least 22% lower and tmax occurred 
at least 1.00 h longer in the RCD and RCS formulations, compared 
with the HSWG formulation (Tables 3 and 4). The dosing schedule 
for galunisertib has been established previously as 150 mg twice 
daily,14 day on/14 day off [8,10]. For this schedule, with multiple 
dosing and a small inter-dosing interval, the potential impact of 
lower Cmax and longer tmax on exposure, and hence on efficacy 
and safety, will be diminished at steady state.
These clinical findings are consistent with our previous 
findings using the artificial stomach–duodenum dissolution 
model. In these in vitro experiments, the PK profiles of the RC 
formulations were similar to that of the HSWG formulation [9]. 
The safety profile of galunisertib dosed at 150 mg BID has been 
established previously [8,10]. In the current study, patients 
were monitored only for the management of adverse events. 
The RC formulations at a single 150 mg dose demonstrated a 
safety profile similar to the HSWG formulation (Table 5). Grade 3 
lymphopenia was the most severe AE in the study experienced 
by 2 patients; one administered with the HSWG formulation 
and another administered with the RCS formulation. 
Overall, the findings from this relative bioavailability study 
suggest that the new processes for manufacturing galunisertib 
tablets should not affect the dosing regimen of galunisertib in 
future clinical trials. 
Figure 3. Individual plasma concentration-time 
profiles for formulations of galunisertib.
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formulations.
Table 5. Number of patients with treatment-
emergent adverse events regardless of 
causality.
Preferred term Galunisertib  
(150 mg), N=14
HSWG RCD RCS All
Lymphopenia (Grade 3) 1 0 1 2
Pyrexia (Grade 1) 0 1 0 1
Vulvovaginitis (Grade 1) 0 1 0 1
Hyperglycemia (Grade 1) 1 0 0 1
Convulsion (Grade 1) 1 0 0 1
Dizziness (Grade 1) 1 0 0 1
Abbreviations: HSWG = high-sheer wet granulation;  
N = number of patients; RCD = roller compaction dry-
milled; RCS = roller compaction slurry-milled.
previously [10]. The purpose of this relative bioavailability study 
was to confirm that with the new manufacturing processes,  
the PK profiles of galunisertib tablets administered as a  
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Supplementary Table S1. Study treatment 
sequences.
Treatment 
sequence
Period 1 Period 2 Period 3
Sequence 1 HSWG RCS RCD
Sequence 2 RCD HSWG RCS
Sequence 3 RCS RCD HSWG
Sequence 4 HSWG RCD RCS
Sequence 5 RCD RCS HSWG
Sequence 6 RCS HSWG RCD
Abbreviations: HSWG = high-sheer wet granulation;  
PK = pharmacokinetic; RCD = roller compaction dry-
milled; RCS = roller compaction slurry-milled. 
Supplementary Table S3. Statistical analysis of tmax 
of LY2157299 including all patients.
Parameter Formulation,
150 mg
N Median
(min, 
max)
Median 
difference 
RCD/RCS – 
HSWG 
(90% CI)
HSWG 14 1.00
(0.50, 
3.08)
tmax 
(h)
RCD 14 2.00 
(0.50, 
3.17)
0.54
(0.00, 1.09)
RCS 14 2.00
(0.50, 
3.00)
0.00
(0.00, 0.71)
Abbreviations: CI = confidence interval; HSWG = high- 
sheer wet granulation; max = maximum; min = minimum; 
RCD = roller compaction dry-milled; N = number 
of patients; tmax = time of maximum plasma drug 
concentration; RCS = roller compaction slurry-milled.
Supplementary Material
Supplementary Table S2. Statistical analysis of 
AUC and Cmax of LY2157299 including all patients.
Parameter Formulation,
150 mg
N Geometric 
LSM 
(90% CI)
Ratio of 
geometric 
LSM
RCD/
RCS:HSWG 
(90% CI)
AUC(0-tlast) 
(µg∙h/L)
HSWG 14 4,516 
(3,320, 6,143)
RCD 14 4,348 
(3,196, 5,915)
0.96 
(0.82, 1.13)
RCS 14 4,344 
(3,193, 5,909)
0.96 
(0.82, 1.13)
AUC(0-48)  
(µg∙h/L)
HSWG 14 4,518
(3,321, 6,148)
RCD 14 4,347 
(3,195, 5,915)
0.96 
(0.82, 1.13)
RCS 14 4,334
(3,185, 5,897)
0.96 
(0.82, 1.13)
AUC(0-∞)  
(µg∙h/L)
HSWG 14 4,766
(3,516, 6,462)
RCD 12 4,631
(3,402, 6,303)
0.97
(0.83, 1.13)
RCS 11 4,816
(3,531, 6,567)
1.01
(0.86, 1.19)
Cmax  
(µg/L)
HSWG 14 960
(686, 1,345)
RCD 14 735
(525, 1,029)
0.77
(0.57, 1.03)
RCS 14 770
(550, 1,078)
0.80
(0.60, 1.07)
For AUC(0-∞), 2 and 3 patients for RCD and RCS, 
respectively had extrapolated AUCtlast-inf values >20% 
and could not be included in the analysis. 
Abbreviations: AUC = area under the plasma concentration 
versus time curve; AUC(0-∞) = AUC from zero to infinity; 
AUC(0-48) = AUC from zero to 48 hours post dose;  
AUC(0-tlast) = AUC from time zero to time t, where t is  
the last time point with a measurable concentration;  
CI = confidence interval; Cmax = maximum plasma drug 
concentration; LSM = least squares means; N = number 
of patients; HSWG = high-sheer wet granulation; PK = 
pharmacokinetic; RCD = roller compaction dry-milled;  
RCS = roller compaction slurry-milled.
